

## Approval of Arthrosamid® for the treatment of knee osteoarthritis

**April 15, 2020:** Contura is pleased to announce the European approval of Arthrosamid for the symptomatic treatment of patients with knee osteoarthritis. The approval was received from the company's notified body, TÜV SÜD, following the completion of a three-month prospective open label study that demonstrated a significant reduction in pain in Arthrosamid treated patients with osteoarthritis of the knee. The study will go on to measure the effectiveness of Arthrosamid in these patients at the 6-month and 12-month time points to demonstrate Arthrosamid's expected longevity of action.

Commenting on the approval, Patrick Banks, Chief Executive of Contura said: "***The results achieved in this open label study, which was conducted on patients with a Kellgren-Lawrence score of 2-4, were in line with the excellent results reported by the Company in a 2018 observational proof-of-concept study with Arthrosamid on the treatment of more than one hundred patients.<sup>1</sup> The study showed that Arthrosamid maintained its effect in reducing pain for over a year. We look forward to this being demonstrated at the six-month and 12-month time points for this study.***"

He further commented on the significance of finding a more suitable treatment for patients with symptomatic knee osteoarthritis: "***Osteoarthritis of the knee is a major medical indication with significant unmet need. Current treatments for this indication show limited efficacy, are generally of short duration and are typically restricted to patients with less severe disease. We are expecting to launch Arthrosamid onto the European market in mid-2021.***"

### About Arthrosamid

Arthrosamid is a polyacrylamide hydrogel developed by Contura as a long-lasting intra-articular injection for the treatment of osteoarthritis in humans. Development of Arthrosamid commenced after the generation of impressive clinical data with Arthramid Vet, a related product of the company, in the treatment of lameness in horses. Arthrosamid becomes embedded in the synovial membrane, providing increased cushioning and other therapeutic benefits to patients with knee osteoarthritis. Patients benefit from both pain relief and improved mobility.

### About Osteoarthritis of the Knee

Osteoarthritis is the most common form of arthritis, characterised by pain and physical disability. More than 10% of people over the age of 55 suffer from symptomatic osteoarthritis, primarily involving the knees. Due to the pivotal role of the knee in basic mobility, knee osteoarthritis is associated with significant impairments and limitations in

basic activities of daily living, such as walking and moving around, self-care and participation in activities, all contributing to a reduced quality of life. There is a shortage of effective treatments available for knee osteoarthritis today. Even the widely used hyaluronic acids are accepted to have limited efficacy and work for limited duration.

### **About Contura**

Contura is headquartered in London and has its manufacturing facility in Copenhagen, Denmark. It specialises in the distribution and sale of healthcare products, both pharmaceuticals and medical devices, focused primarily on women's health and pain. Its lead products are Bulkamid®, Arthrosamid®, Aquamid®, Regurin® XL and Cystistat®. Arthrosamid®, the Company's treatment for osteoarthritis of the knee, is the most recent addition to its suite of products and is due to be launched onto the European market in mid-2021. Contura has an established sales and marketing infrastructure in the leading European and worldwide markets. It has its own offices in the UK, United States, Denmark, Germany, France and Italy, currently employing around 55 staff worldwide.

### **References**

1. Henriksen et al. Intra-articular 2.5% polyacrylamide hydrogel for the treatment of knee osteoarthritis: an observational proof-of-concept cohort study. *Clinical and Experimental Rheumatology* 2018.

-ENDS-

### **Contact:**

For further information please contact the Contura Press Office (managed by Trinity PR) on +44 20 7112 4905 / +44 770 948 7959 / [jo.hudson@trinitypr.co.uk](mailto:jo.hudson@trinitypr.co.uk)

[www.contura.com](http://www.contura.com)